Modified Port Implantation Technique Improves Intraperitoneal Chemotherapy Outcomes in Ovarian Cancer

Strategic Insights -

Recent research from Koc University Hospital in Istanbul, Turkiye, has shed light on the effectiveness of a modified port implantation technique in improving intraperitoneal chemotherapy (IPCT) outcomes for patients with stage III and IV ovarian cancers. The study found that patients who received 7 cycles or more of IPCT using the modified port technique had a significantly longer average survival period compared to those who received fewer cycles. The researchers highlighted the potential of IPCT as a promising office-based maintenance therapy option with significant survival benefits.

Key Takeaways:

  • The modified port implantation technique may help reduce chemotherapy and port complications, allowing for outpatient IPCT delivery.
  • Patients who completed 7 or more cycles of IPCT using the modified port technique had a significantly longer average survival period (64.76 +/- 5.38 months) compared to those who completed fewer cycles (41.27 +/- 5.77 months).
  • Port-related issues were the primary reason for therapy discontinuation in most cases (11.1%), followed by additional factors such as neoadjuvant chemotherapy, adhesions, infections, abdominal pain, and family history of genitourinary cancer.
  • The study included 72 patients who underwent IPCT at the Women's Cancer Centre from January 2005 to May 2016, with a median number of IPCT cycles administered being six.
  • 52 patients (73.2%) completed 4 cycles, 47 patients (66.2%) completed 6 cycles, and 29 patients (40.84%) completed 8 cycles.

Statistics:

  • 72 patients underwent IPCT at the Women's Cancer Centre from January 2005 to May 2016.
  • The median number of IPCT cycles administered was six.
  • 52 patients (73.2%) completed 4 cycles, 47 patients (66.2%) completed 6 cycles, and 29 patients (40.84%) completed 8 cycles.
  • Patients receiving 7 cycles or more had a significantly longer average survival period (64.76 +/- 5.38 months) compared to those receiving 6 cycles or fewer (41.27 +/- 5.77 months).
  • Port-related issues were the primary reason for therapy discontinuation in 11.1% of cases.

Sources:

  • [NewsRx. Researchers from Koc University Hospital Describe Findings in Ovarian Cancer (Modified Port Implantation for Intraperitoneal Chemotherapy: a Retrospective Analysis of Cycle Completion and Survival In Ovarian Cancer). OBGYN & Reproduction Week. October 27, 2025; p 931.]
  • [European Journal of Gynaecological Oncology. Modified Port Implantation for Intraperitoneal Chemotherapy: a Retrospective Analysis of Cycle Completion and Survival In Ovarian Cancer. 2025;46(8):68-77.]